"Unfortunately the value of the stock price is not reflecting all the efforts that we are putting to advance the science and the innovation we have in the company."
Actually even if he's telling the truth about SPPH's so-called monolithic SR technology being in the throes of animal testing, then even now the pps is still way too high as it gives a market cap of just under $7 million.
The value of a technology that has not advanced beyond simple animal models and is only being developed for two drugs -metformin and ibuprofen- which have countless competitors already approved and on on the market worldwide, in both immediate and sustained release forms, is extremely low.
You see, the only way any new entrants into these two markets (SR metfomrin and ibuprofen) will be able to compete is on price- they are literally commodities - and yet they require literally years of further testing in humans, in comparative controlled clinical studies against active comparators if they wish to make any claims at all, and this will cost tens of millions of dollars.
And there's every chance that the technology could fail in many different ways along the development path, including dose dumping, lack of bioequivalence, unexpected side-effects due to the excipients, IP challenges and so on and so forth.
And there's dozens of different types of SR tech out there already, and no one needs yet another.
As a business model, it makes no sense at all.
What SPPH have- and what their own PRs admit - is a very small patent estate around technology no one needs, and that SPPH themselves value at less than $200,000, and two or three part time folk working part time in rented labs in a Canadian educational institution.
If I were to be extraordinarily generous, I might give the whole enterprise a value of $300,000 and that's giving full credence to SPPH's own valuation of their patent, which I think is a gross over-statement.
That would give a fully-loaded pps value of around one tenth of one cent, suggesting that the current pps of SPPH is about 20 or 30 times higher than it deserves to be.
Of course, any real company looking at SPPH would make the same calculation, which is why it takes anyone who knows anything about biopharmaceuticals two microseconds to realise the whole buy-out story - at $245 million, a thousand times more than the company is really worth!- is a complete and total scam from start to finish.
A few more moments' research into the histories of Arella, Amyot, Albi and Morrice in countless different penny stock scams run from North of the Border tells you everything else you need to know.
In fact, I doubt that even the monolithic SR story is real, so in practical terms the company is worthless.
Unless, of course, like Amyot, through IAB Media, and Arella et al you use it to bilk ordinary private retail investors of millions of dollars, in which case it's a very worthwhile proposition.
PS Diane, I implore you to speak to anyone you know who knows anything either about the Pharma world, even your family physician, and ask him or her how much a new SR formulation of metformin or ibuprofen would be worth, and what would make him or her prescribe it. Similarly, find someone who knows a little about the world of mergers and acquisitions, preferably in biopharma, and ask them both about the valuation and the story behind the so-called Hail First Pharma narrative. Please.
News 
Market Data 
Discover 
